Tuning of G-CSFR signaling by de novo-designed agonists
Enhancing cytokine-based therapies by systematically tuning how an agonist associates its receptor is emerging as a powerful new concept in drug discovery. Here, we report the design and characterization of agonists that tune granulocyte-colony-stimulating factor receptor (G-CSFR) activity, which is central for the proliferation and granulocytic differentiation of hematopoietic stem cells. Using design agonists, we study the impact of varying the receptor-binding affinity and dimerization geometry on receptor association, downstream signaling, and cellular response. Hence, we achieved agonists with altered signaling specificities that are hyper-thermostable, can outcompete the native ligand (G-CSF), and bias cells toward granulopoietic differentiation over triggering proliferation. Furthermore, the design agonists differentially modulate the kinetics and amplitudes of signal transduction pathways and gene expression patterns. In contrast to G-CSF, they achieve more selective activation of gene sets with hematopoietic functions, with minimal unwanted effects on immunomodulatory signaling. These findings demonstrate the potential of dissecting the complex G-CSFR signaling, and they open up ways for new therapeutic applications for designed cytokines.
Authors
- Karl Welte (ORCID: https://orcid.org/0000-0001-5178-3074)
- Siarhei Kandabarau (ORCID: https://orcid.org/0000-0002-1379-7974)
- Kateryna Maksymenko (ORCID: https://orcid.org/0000-0002-0543-1323)
- Andrei N. Lupas (ORCID: https://orcid.org/0000-0002-1959-4836)
- Christoph Pollmann (ORCID: https://orcid.org/0000-0002-1473-0288)
- Jérémy Haaf
- Maksim Klimiankou
- Julia Skokowa (ORCID: https://orcid.org/0000-0002-4399-2324)
- Narges Aghaallaei (ORCID: https://orcid.org/0000-0002-9890-3229)
- Timo Ullrich
- Mohammad ElGamacy (ORCID: https://orcid.org/0000-0002-3446-8774)
- Ivan Tesakov (ORCID: https://orcid.org/0000-0002-9366-3449)
- Patrick Müller (ORCID: https://orcid.org/0000-0002-0702-6209)
- Claudia Lengerke (ORCID: https://orcid.org/0000-0001-5442-2805)
- Jacob Piehler (ORCID: https://orcid.org/0000-0002-2143-2270)
- Maya El-Riz
- Valeriia Hatskovska
- Birte Hernandez-Alvarez
- Malte Ritter (ORCID: https://orcid.org/0000-0002-3670-7564)
Institutions
- Max Planck Society (DE)
- Osnabrück University (DE)
- Max Planck Institute for Developmental Biology (DE)
- University Children's Hospital Tübingen (DE)
- Friedrich Miescher Laboratory (DE)
- Max Planck Institute for Biology (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- Molecular Therapy
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1016/j.ymthe.2025.08.031
- Primary Topic
- Eicosanoids and Hypertension Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft
- José Carreras Leukämie-Stiftung
- H2020 European Research Council